Mechanism for identifying drugs for the treatment of type II diabetes

US7601687B2 · kind B2 · utility

Assignee

• BIOCRINE AB · SE

Inventors

• Per-Olof Berggren · Solna, SE
• Barbara Leibiger · Solna, SE
• Ingo Leibiger · Solna, SE

Key dates

• Filing date: Jul 25, 2006
• Grant date: Oct 13, 2009
• Expiry date: Aug 9, 2026

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/72
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Insulin resistance is a central feature of type II diabetes and other diseases, and may affect every tissue of the body, including the pancreatic beta cell. Insulin signaling is mediated by a complex network of diverging and converging pathways, with alternative proteins and isoforms at almost every step in the process. We have previously shown that insulin activates the transcription of its own gene by signaling through Insulin Receptor A type (Ex11−), PI3 kinase and p70 s6 kinase. When studying the mechanisms underlying the glucose-stimulated activation of the glucokinase gene in pancreatic beta cells, we now demonstrate that also here secreted insulin is a key-factor. In contrast to the insulin gene, transcription of the glucokinase gene is promoted by signaling via Insulin Receptor B type (Ex11+) and protein kinase B (c-Akt). These data provide the first evidence for selectivity in insulin action via the two isoforms of the Insulin Receptor, A type (Ex11−) and B type (Ex11+), and reinforce the concept of the beta cell being an important target of insulin action.